

Generic Drugs Industry Research Report 2024

<https://marketpublishers.com/r/G2774009A9FAEN.html>

Date: April 2024

Pages: 146

Price: US\$ 2,950.00 (Single User License)

ID: G2774009A9FAEN

Abstracts

Summary

A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.

According to APO Research, The global Generic Drugs market was valued at US\$ million in 2023 and is anticipated to reach US\$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.

North American market for Generic Drugs is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Generic Drugs is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Generic Drugs is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global companies of Generic Drugs include Teva, Novartis - Sandoz, Mylan, Sun Pharmaceutical, Aspen, Fresenius Kabi, Pfizer (Hospira), Sanofi and Aurobindo, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Generic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic Drugs.

The Generic Drugs market size, estimations, and forecasts are provided in terms of revenue (\$ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Generic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Teva

Novartis - Sandoz

Mylan

Sun Pharmaceutical

Aspen

Fresenius Kabi

Pfizer (Hospira)

Sanofi

Aurobindo

Lupin

Dr. Reddy's

Apotex

Cipla

ENDO (Par Pharmaceutical)

Stada Arzneimittel

Krka Group

Nichi-Iko Pharmaceutical

Valeant

Zydus Cadila

Hikma

Pharmaniaga Berhad

Hovid Berhad

Duopharma Biotech

Kotra Pharma

HOE Pharmaceutical

Y.S.P. Industries

Generic Drugs segment by Type

Prescription

Non-Prescription Drugs

Generic Drugs Segment by Application

Hospital

Clinic

Others

Generic Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Generic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Drugs.
7. This report helps stakeholders to identify some of the key players in the market and

understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Generic Drugs companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

Contents

1 PREFACE

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 MARKET OVERVIEW

- 2.1 Product Definition
- 2.2 Generic Drugs by Type
 - 2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
 - 2.2.2 Prescription
 - 2.2.3 Non-Prescription Drugs
- 2.3 Generic Drugs by Application
 - 2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
 - 2.3.2 Hospital
 - 2.3.3 Clinic
 - 2.3.4 Others
- 2.4 Assumptions and Limitations

3 GENERIC DRUGS BREAKDOWN DATA BY TYPE

- 3.1 Global Generic Drugs Historic Market Size by Type (2019-2024)
- 3.2 Global Generic Drugs Forecasted Market Size by Type (2025-2030)

4 GENERIC DRUGS BREAKDOWN DATA BY APPLICATION

- 4.1 Global Generic Drugs Historic Market Size by Application (2019-2024)
- 4.2 Global Generic Drugs Forecasted Market Size by Application (2019-2024)

5 GLOBAL GROWTH TRENDS

- 5.1 Global Generic Drugs Market Perspective (2019-2030)

5.2 Global Generic Drugs Growth Trends by Region

5.2.1 Global Generic Drugs Market Size by Region: 2019 VS 2023 VS 2030

5.2.2 Generic Drugs Historic Market Size by Region (2019-2024)

5.2.3 Generic Drugs Forecasted Market Size by Region (2025-2030)

5.3 Generic Drugs Market Dynamics

5.3.1 Generic Drugs Industry Trends

5.3.2 Generic Drugs Market Drivers

5.3.3 Generic Drugs Market Challenges

5.3.4 Generic Drugs Market Restraints

6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS

6.1 Global Top Generic Drugs Players by Revenue

6.1.1 Global Top Generic Drugs Players by Revenue (2019-2024)

6.1.2 Global Generic Drugs Revenue Market Share by Players (2019-2024)

6.2 Global Generic Drugs Industry Players Ranking, 2022 VS 2023 VS 2024

6.3 Global Key Players of Generic Drugs Head office and Area Served

6.4 Global Generic Drugs Players, Product Type & Application

6.5 Global Generic Drugs Players, Date of Enter into This Industry

6.6 Global Generic Drugs Market CR5 and HHI

6.7 Global Players Mergers & Acquisition

7 NORTH AMERICA

7.1 North America Generic Drugs Market Size (2019-2030)

7.2 North America Generic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 North America Generic Drugs Market Size by Country (2019-2024)

7.4 North America Generic Drugs Market Size by Country (2025-2030)

7.5 United States

7.6 Canada

8 EUROPE

8.1 Europe Generic Drugs Market Size (2019-2030)

8.2 Europe Generic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

8.3 Europe Generic Drugs Market Size by Country (2019-2024)

8.4 Europe Generic Drugs Market Size by Country (2025-2030)

8.5 Germany

- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Russia
- 8.10 Nordic Countries

9 ASIA-PACIFIC

- 9.1 Asia-Pacific Generic Drugs Market Size (2019-2030)
- 9.2 Asia-Pacific Generic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 9.3 Asia-Pacific Generic Drugs Market Size by Country (2019-2024)
- 9.4 Asia-Pacific Generic Drugs Market Size by Country (2025-2030)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 Southeast Asia
- 9.9 India
- 9.10 Australia

10 LATIN AMERICA

- 10.1 Latin America Generic Drugs Market Size (2019-2030)
- 10.2 Latin America Generic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 10.3 Latin America Generic Drugs Market Size by Country (2019-2024)
- 10.4 Latin America Generic Drugs Market Size by Country (2025-2030)
- 10.5 Mexico
- 10.6 Brazil

11 MIDDLE EAST & AFRICA

- 11.1 Middle East & Africa Generic Drugs Market Size (2019-2030)
- 11.2 Middle East & Africa Generic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 11.3 Middle East & Africa Generic Drugs Market Size by Country (2019-2024)
- 11.4 Middle East & Africa Generic Drugs Market Size by Country (2025-2030)
- 11.5 Turkey
- 11.6 Saudi Arabia
- 11.7 UAE

12 PLAYERS PROFILED

12.1 Teva

- 12.1.1 Teva Company Information
- 12.1.2 Teva Business Overview
- 12.1.3 Teva Revenue in Generic Drugs Business (2019-2024)
- 12.1.4 Teva Generic Drugs Product Portfolio
- 12.1.5 Teva Recent Developments

12.2 Novartis - Sandoz

- 12.2.1 Novartis - Sandoz Company Information
- 12.2.2 Novartis - Sandoz Business Overview
- 12.2.3 Novartis - Sandoz Revenue in Generic Drugs Business (2019-2024)
- 12.2.4 Novartis - Sandoz Generic Drugs Product Portfolio
- 12.2.5 Novartis - Sandoz Recent Developments

12.3 Mylan

- 12.3.1 Mylan Company Information
- 12.3.2 Mylan Business Overview
- 12.3.3 Mylan Revenue in Generic Drugs Business (2019-2024)
- 12.3.4 Mylan Generic Drugs Product Portfolio
- 12.3.5 Mylan Recent Developments

12.4 Sun Pharmaceutical

- 12.4.1 Sun Pharmaceutical Company Information
- 12.4.2 Sun Pharmaceutical Business Overview
- 12.4.3 Sun Pharmaceutical Revenue in Generic Drugs Business (2019-2024)
- 12.4.4 Sun Pharmaceutical Generic Drugs Product Portfolio
- 12.4.5 Sun Pharmaceutical Recent Developments

12.5 Aspen

- 12.5.1 Aspen Company Information
- 12.5.2 Aspen Business Overview
- 12.5.3 Aspen Revenue in Generic Drugs Business (2019-2024)
- 12.5.4 Aspen Generic Drugs Product Portfolio
- 12.5.5 Aspen Recent Developments

12.6 Fresenius Kabi

- 12.6.1 Fresenius Kabi Company Information
- 12.6.2 Fresenius Kabi Business Overview
- 12.6.3 Fresenius Kabi Revenue in Generic Drugs Business (2019-2024)
- 12.6.4 Fresenius Kabi Generic Drugs Product Portfolio
- 12.6.5 Fresenius Kabi Recent Developments

12.7 Pfizer (Hospira)

12.7.1 Pfizer (Hospira) Company Information

12.7.2 Pfizer (Hospira) Business Overview

12.7.3 Pfizer (Hospira) Revenue in Generic Drugs Business (2019-2024)

12.7.4 Pfizer (Hospira) Generic Drugs Product Portfolio

12.7.5 Pfizer (Hospira) Recent Developments

12.8 Sanofi

12.8.1 Sanofi Company Information

12.8.2 Sanofi Business Overview

12.8.3 Sanofi Revenue in Generic Drugs Business (2019-2024)

12.8.4 Sanofi Generic Drugs Product Portfolio

12.8.5 Sanofi Recent Developments

12.9 Aurobindo

12.9.1 Aurobindo Company Information

12.9.2 Aurobindo Business Overview

12.9.3 Aurobindo Revenue in Generic Drugs Business (2019-2024)

12.9.4 Aurobindo Generic Drugs Product Portfolio

12.9.5 Aurobindo Recent Developments

12.10 Lupin

12.10.1 Lupin Company Information

12.10.2 Lupin Business Overview

12.10.3 Lupin Revenue in Generic Drugs Business (2019-2024)

12.10.4 Lupin Generic Drugs Product Portfolio

12.10.5 Lupin Recent Developments

12.11 Dr. Reddy's

12.11.1 Dr. Reddy's Company Information

12.11.2 Dr. Reddy's Business Overview

12.11.3 Dr. Reddy's Revenue in Generic Drugs Business (2019-2024)

12.11.4 Dr. Reddy's Generic Drugs Product Portfolio

12.11.5 Dr. Reddy's Recent Developments

12.12 Apotex

12.12.1 Apotex Company Information

12.12.2 Apotex Business Overview

12.12.3 Apotex Revenue in Generic Drugs Business (2019-2024)

12.12.4 Apotex Generic Drugs Product Portfolio

12.12.5 Apotex Recent Developments

12.13 Cipla

12.13.1 Cipla Company Information

12.13.2 Cipla Business Overview

- 12.13.3 Cipla Revenue in Generic Drugs Business (2019-2024)
- 12.13.4 Cipla Generic Drugs Product Portfolio
- 12.13.5 Cipla Recent Developments
- 12.14 ENDO (Par Pharmaceutical)
 - 12.14.1 ENDO (Par Pharmaceutical) Company Information
 - 12.14.2 ENDO (Par Pharmaceutical) Business Overview
 - 12.14.3 ENDO (Par Pharmaceutical) Revenue in Generic Drugs Business (2019-2024)
 - 12.14.4 ENDO (Par Pharmaceutical) Generic Drugs Product Portfolio
 - 12.14.5 ENDO (Par Pharmaceutical) Recent Developments
- 12.15 Stada Arzneimittel
 - 12.15.1 Stada Arzneimittel Company Information
 - 12.15.2 Stada Arzneimittel Business Overview
 - 12.15.3 Stada Arzneimittel Revenue in Generic Drugs Business (2019-2024)
 - 12.15.4 Stada Arzneimittel Generic Drugs Product Portfolio
 - 12.15.5 Stada Arzneimittel Recent Developments
- 12.16 Krka Group
 - 12.16.1 Krka Group Company Information
 - 12.16.2 Krka Group Business Overview
 - 12.16.3 Krka Group Revenue in Generic Drugs Business (2019-2024)
 - 12.16.4 Krka Group Generic Drugs Product Portfolio
 - 12.16.5 Krka Group Recent Developments
- 12.17 Nichi-Iko Pharmaceutical
 - 12.17.1 Nichi-Iko Pharmaceutical Company Information
 - 12.17.2 Nichi-Iko Pharmaceutical Business Overview
 - 12.17.3 Nichi-Iko Pharmaceutical Revenue in Generic Drugs Business (2019-2024)
 - 12.17.4 Nichi-Iko Pharmaceutical Generic Drugs Product Portfolio
 - 12.17.5 Nichi-Iko Pharmaceutical Recent Developments
- 12.18 Valeant
 - 12.18.1 Valeant Company Information
 - 12.18.2 Valeant Business Overview
 - 12.18.3 Valeant Revenue in Generic Drugs Business (2019-2024)
 - 12.18.4 Valeant Generic Drugs Product Portfolio
 - 12.18.5 Valeant Recent Developments
- 12.19 Zydus Cadila
 - 12.19.1 Zydus Cadila Company Information
 - 12.19.2 Zydus Cadila Business Overview
 - 12.19.3 Zydus Cadila Revenue in Generic Drugs Business (2019-2024)
 - 12.19.4 Zydus Cadila Generic Drugs Product Portfolio
 - 12.19.5 Zydus Cadila Recent Developments

12.20 Hikma

12.20.1 Hikma Company Information

12.20.2 Hikma Business Overview

12.20.3 Hikma Revenue in Generic Drugs Business (2019-2024)

12.20.4 Hikma Generic Drugs Product Portfolio

12.20.5 Hikma Recent Developments

12.21 Pharmaniaga Berhad

12.21.1 Pharmaniaga Berhad Company Information

12.21.2 Pharmaniaga Berhad Business Overview

12.21.3 Pharmaniaga Berhad Revenue in Generic Drugs Business (2019-2024)

12.21.4 Pharmaniaga Berhad Generic Drugs Product Portfolio

12.21.5 Pharmaniaga Berhad Recent Developments

12.22 Hovid Berhad

12.22.1 Hovid Berhad Company Information

12.22.2 Hovid Berhad Business Overview

12.22.3 Hovid Berhad Revenue in Generic Drugs Business (2019-2024)

12.22.4 Hovid Berhad Generic Drugs Product Portfolio

12.22.5 Hovid Berhad Recent Developments

12.23 Duopharma Biotech

12.23.1 Duopharma Biotech Company Information

12.23.2 Duopharma Biotech Business Overview

12.23.3 Duopharma Biotech Revenue in Generic Drugs Business (2019-2024)

12.23.4 Duopharma Biotech Generic Drugs Product Portfolio

12.23.5 Duopharma Biotech Recent Developments

12.24 Kotra Pharma

12.24.1 Kotra Pharma Company Information

12.24.2 Kotra Pharma Business Overview

12.24.3 Kotra Pharma Revenue in Generic Drugs Business (2019-2024)

12.24.4 Kotra Pharma Generic Drugs Product Portfolio

12.24.5 Kotra Pharma Recent Developments

12.25 HOE Pharmaceutical

12.25.1 HOE Pharmaceutical Company Information

12.25.2 HOE Pharmaceutical Business Overview

12.25.3 HOE Pharmaceutical Revenue in Generic Drugs Business (2019-2024)

12.25.4 HOE Pharmaceutical Generic Drugs Product Portfolio

12.25.5 HOE Pharmaceutical Recent Developments

12.26 Y.S.P. Industries

12.26.1 Y.S.P. Industries Company Information

12.26.2 Y.S.P. Industries Business Overview

12.26.3 Y.S.P. Industries Revenue in Generic Drugs Business (2019-2024)

12.26.4 Y.S.P. Industries Generic Drugs Product Portfolio

12.26.5 Y.S.P. Industries Recent Developments

13 REPORT CONCLUSION

14 DISCLAIMER

List Of Tables

LIST OF TABLES

Table 1. Secondary Sources

Table 2. Primary Sources

Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US\$ Million)

Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US\$ Million)

Table 5. Global Generic Drugs Market Size by Type (2018-2023) & (US\$ Million)

Table 6. Global Generic Drugs Revenue Market Share by Type (2018-2023)

Table 7. Global Generic Drugs Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 8. Global Generic Drugs Revenue Market Share by Type (2024-2029)

Table 9. Global Generic Drugs Market Size by Application (2018-2023) & (US\$ Million)

Table 10. Global Generic Drugs Revenue Market Share by Application (2018-2023)

Table 11. Global Generic Drugs Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 12. Global Generic Drugs Revenue Market Share by Application (2024-2029)

Table 13. Global Generic Drugs Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 14. Global Generic Drugs Market Size by Region (2018-2023) & (US\$ Million)

Table 15. Global Generic Drugs Market Share by Region (2018-2023)

Table 16. Global Generic Drugs Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 17. Global Generic Drugs Market Share by Region (2024-2029)

Table 18. Generic Drugs Market Trends

Table 19. Generic Drugs Market Drivers

Table 20. Generic Drugs Market Challenges

Table 21. Generic Drugs Market Restraints

Table 22. Global Top Generic Drugs Manufacturers by Revenue (US\$ Million) & (2018-2023)

Table 23. Global Generic Drugs Revenue Market Share by Manufacturers (2018-2023)

Table 24. Global Generic Drugs Industry Manufacturers Ranking, 2021 VS 2022 VS 2023

Table 25. Global Key Players of Generic Drugs, Headquarters and Area Served

Table 26. Global Generic Drugs Manufacturers, Product Type & Application

Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 28. Global Generic Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) &

(based on the Revenue of 2022)

Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 30. North America Generic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 31. North America Generic Drugs Market Size by Country (2018-2023) & (US\$ Million)

Table 32. North America Generic Drugs Market Size by Country (2024-2029) & (US\$ Million)

Table 33. Europe Generic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 34. Europe Generic Drugs Market Size by Country (2018-2023) & (US\$ Million)

Table 35. Europe Generic Drugs Market Size by Country (2024-2029) & (US\$ Million)

Table 36. Asia-Pacific Generic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 37. Asia-Pacific Generic Drugs Market Size by Country (2018-2023) & (US\$ Million)

Table 38. Asia-Pacific Generic Drugs Market Size by Country (2024-2029) & (US\$ Million)

Table 39. Latin America Generic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 40. Latin America Generic Drugs Market Size by Country (2018-2023) & (US\$ Million)

Table 41. Latin America Generic Drugs Market Size by Country (2024-2029) & (US\$ Million)

Table 42. Middle East & Africa Generic Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 43. Middle East & Africa Generic Drugs Market Size by Country (2018-2023) & (US\$ Million)

Table 44. Middle East & Africa Generic Drugs Market Size by Country (2024-2029) & (US\$ Million)

Table 45. Teva Company Detail

Table 46. Teva Business Overview

Table 47. Teva Generic Drugs Product

Table 48. Teva Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)

Table 49. Teva Recent Development

Table 50. Novartis - Sandoz Company Detail

Table 51. Novartis - Sandoz Business Overview

Table 52. Novartis - Sandoz Generic Drugs Product

Table 53. Novartis - Sandoz Revenue in Generic Drugs Business (2017-2022) & (US\$

Million)

Table 54. Novartis - Sandoz Recent Development

Table 55. Mylan Company Detail

Table 56. Mylan Business Overview

Table 57. Mylan Generic Drugs Product

Table 58. Mylan Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)

Table 59. Mylan Recent Development

Table 60. Sun Pharmaceutical Company Detail

Table 61. Sun Pharmaceutical Business Overview

Table 62. Sun Pharmaceutical Generic Drugs Product

Table 63. Sun Pharmaceutical Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)

Table 64. Sun Pharmaceutical Recent Development

Table 65. Aspen Company Detail

Table 66. Aspen Business Overview

Table 67. Aspen Generic Drugs Product

Table 68. Aspen Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)

Table 69. Aspen Recent Development

Table 70. Fresenius Kabi Company Detail

Table 71. Fresenius Kabi Business Overview

Table 72. Fresenius Kabi Generic Drugs Product

Table 73. Fresenius Kabi Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)

Table 74. Fresenius Kabi Recent Development

Table 75. Pfizer (Hospira) Company Detail

Table 76. Pfizer (Hospira) Business Overview

Table 77. Pfizer (Hospira) Generic Drugs Product

Table 78. Pfizer (Hospira) Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)

Table 79. Pfizer (Hospira) Recent Development

Table 80. Sanofi Company Detail

Table 81. Sanofi Business Overview

Table 82. Sanofi Generic Drugs Product

Table 83. Sanofi Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)

Table 84. Sanofi Recent Development

Table 85. Aurobindo Company Detail

Table 86. Aurobindo Business Overview

Table 87. Aurobindo Generic Drugs Product

Table 88. Aurobindo Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)

- Table 89. Aurobindo Recent Development
- Table 90. Lupin Company Detail
- Table 91. Lupin Business Overview
- Table 92. Lupin Generic Drugs Product
- Table 93. Lupin Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)
- Table 94. Lupin Recent Development
- Table 95. Dr. Reddy's Company Detail
- Table 96. Dr. Reddy's Business Overview
- Table 97. Dr. Reddy's Generic Drugs Product
- Table 98. Dr. Reddy's Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)
- Table 99. Dr. Reddy's Recent Development
- Table 100. Apotex Company Detail
- Table 101. Apotex Business Overview
- Table 102. Apotex Generic Drugs Product
- Table 103. Apotex Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)
- Table 104. Apotex Recent Development
- Table 105. Cipla Company Detail
- Table 106. Cipla Business Overview
- Table 107. Cipla Generic Drugs Product
- Table 108. Cipla Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)
- Table 109. Cipla Recent Development
- Table 110. ENDO (Par Pharmaceutical) Company Detail
- Table 111. ENDO (Par Pharmaceutical) Business Overview
- Table 112. ENDO (Par Pharmaceutical) Generic Drugs Product
- Table 113. ENDO (Par Pharmaceutical) Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)
- Table 114. ENDO (Par Pharmaceutical) Recent Development
- Table 115. Stada Arzneimittel Company Detail
- Table 116. Stada Arzneimittel Business Overview
- Table 117. Stada Arzneimittel Generic Drugs Product
- Table 118. Stada Arzneimittel Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)
- Table 119. Stada Arzneimittel Recent Development
- Table 120. Krka Group Company Detail
- Table 121. Krka Group Business Overview
- Table 122. Krka Group Generic Drugs Product
- Table 123. Krka Group Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)
- Table 124. Krka Group Recent Development

- Table 125. Nichi-Iko Pharmaceutical Company Detail
- Table 126. Nichi-Iko Pharmaceutical Business Overview
- Table 127. Nichi-Iko Pharmaceutical Generic DrugsProduct
- Table 128. Nichi-Iko Pharmaceutical Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)
- Table 129. Nichi-Iko Pharmaceutical Recent Development
- Table 130. Valeant Company Detail
- Table 131. Valeant Business Overview
- Table 132. Valeant Generic DrugsProduct
- Table 133. Valeant Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)
- Table 134. Valeant Recent Development
- Table 135. Zydus Cadila Company Detail
- Table 136. Zydus Cadila Business Overview
- Table 137. Zydus Cadila Generic DrugsProduct
- Table 138. Zydus Cadila Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)
- Table 139. Zydus Cadila Recent Development
- Table 140. Hikma Company Detail
- Table 141. Hikma Business Overview
- Table 142. Hikma Generic DrugsProduct
- Table 143. Hikma Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)
- Table 144. Hikma Recent Development
- Table 145. Pharmaniaga Berhad Company Detail
- Table 146. Pharmaniaga Berhad Business Overview
- Table 147. Pharmaniaga Berhad Generic DrugsProduct
- Table 148. Pharmaniaga Berhad Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)
- Table 149. Pharmaniaga Berhad Recent Development
- Table 150. Hovid Berhad Company Detail
- Table 151. Hovid Berhad Business Overview
- Table 152. Hovid Berhad Generic DrugsProduct
- Table 153. Hovid Berhad Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)
- Table 154. Hovid Berhad Recent Development
- Table 155. Duopharma Biotech Company Detail
- Table 156. Duopharma Biotech Business Overview
- Table 157. Duopharma Biotech Generic DrugsProduct
- Table 158. Duopharma Biotech Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)

- Table 159. Duopharma Biotech Recent Development
- Table 160. Kotra Pharma Company Detail
- Table 161. Kotra Pharma Business Overview
- Table 162. Kotra Pharma Generic DrugsProduct
- Table 163. Kotra Pharma Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)
- Table 164. Kotra Pharma Recent Development
- Table 165. HOE Pharmaceutical Company Detail
- Table 166. HOE Pharmaceutical Business Overview
- Table 167. HOE Pharmaceutical Generic DrugsProduct
- Table 168. HOE Pharmaceutical Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)
- Table 169. HOE Pharmaceutical Recent Development
- Table 170. Y.S.P. Industries Company Detail
- Table 171. Y.S.P. Industries Business Overview
- Table 172. Y.S.P. Industries Generic DrugsProduct
- Table 173. Y.S.P. Industries Revenue in Generic Drugs Business (2017-2022) & (US\$ Million)
- Table 174. Y.S.P. Industries Recent Development
- Table 175. Teva Company Information
- Table 176. Teva Business Overview
- Table 177. Teva Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)
- Table 178. Teva Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 179. Teva Recent Development
- Table 180. Novartis - Sandoz Company Information
- Table 181. Novartis - Sandoz Business Overview
- Table 182. Novartis - Sandoz Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)
- Table 183. Novartis - Sandoz Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 184. Novartis - Sandoz Recent Development
- Table 185. Mylan Company Information
- Table 186. Mylan Business Overview
- Table 187. Mylan Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)
- Table 188. Mylan Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 189. Mylan Recent Development

Table 190. Sun Pharmaceutical Company Information

Table 191. Sun Pharmaceutical Business Overview

Table 192. Sun Pharmaceutical Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)

Table 193. Sun Pharmaceutical Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 194. Sun Pharmaceutical Recent Development

Table 195. Aspen Company Information

Table 196. Aspen Business Overview

Table 197. Aspen Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)

Table 198. Aspen Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 199. Aspen Recent Development

Table 200. Fresenius Kabi Company Information

Table 201. Fresenius Kabi Business Overview

Table 202. Fresenius Kabi Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)

Table 203. Fresenius Kabi Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 204. Fresenius Kabi Recent Development

Table 205. Pfizer (Hospira) Company Information

Table 206. Pfizer (Hospira) Business Overview

Table 207. Pfizer (Hospira) Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)

Table 208. Pfizer (Hospira) Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 209. Pfizer (Hospira) Recent Development

Table 210. Sanofi Company Information

Table 211. Sanofi Business Overview

Table 212. Sanofi Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)

Table 213. Sanofi Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 214. Sanofi Recent Development

Table 215. Aurobindo Company Information

Table 216. Aurobindo Business Overview

Table 217. Aurobindo Generic Drugs Revenue in Generic Drugs Business (2018-2023)

& (US\$ Million)

Table 218. Aurobindo Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 219. Aurobindo Recent Development

Table 220. Lupin Company Information

Table 221. Lupin Business Overview

Table 222. Lupin Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)

Table 223. Lupin Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 224. Lupin Recent Development

Table 225. Dr. Reddy's Company Information

Table 226. Dr. Reddy's Business Overview

Table 227. Dr. Reddy's Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)

Table 228. Dr. Reddy's Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 229. Dr. Reddy's Recent Development

Table 230. Apotex Company Information

Table 231. Apotex Business Overview

Table 232. Apotex Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)

Table 233. Apotex Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 234. Apotex Recent Development

Table 235. Cipla Company Information

Table 236. Cipla Business Overview

Table 237. Cipla Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)

Table 238. Cipla Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 239. Cipla Recent Development

Table 240. ENDO (Par Pharmaceutical) Company Information

Table 241. ENDO (Par Pharmaceutical) Business Overview

Table 242. ENDO (Par Pharmaceutical) Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)

Table 243. ENDO (Par Pharmaceutical) Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 244. ENDO (Par Pharmaceutical) Recent Development

- Table 245. Stada Arzneimittel Company Information
- Table 246. Stada Arzneimittel Business Overview
- Table 247. Stada Arzneimittel Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)
- Table 248. Stada Arzneimittel Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 249. Stada Arzneimittel Recent Development
- Table 250. Krka Group Company Information
- Table 251. Krka Group Business Overview
- Table 252. Krka Group Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)
- Table 253. Krka Group Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 254. Krka Group Recent Development
- Table 255. Nichi-Iko Pharmaceutical Company Information
- Table 256. Nichi-Iko Pharmaceutical Business Overview
- Table 257. Nichi-Iko Pharmaceutical Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)
- Table 258. Nichi-Iko Pharmaceutical Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 259. Nichi-Iko Pharmaceutical Recent Development
- Table 260. Valeant Company Information
- Table 261. Valeant Business Overview
- Table 262. Valeant Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)
- Table 263. Valeant Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 264. Valeant Recent Development
- Table 265. Zydus Cadila Company Information
- Table 266. Zydus Cadila Business Overview
- Table 267. Zydus Cadila Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)
- Table 268. Zydus Cadila Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 269. Zydus Cadila Recent Development
- Table 270. Hikma Company Information
- Table 271. Hikma Business Overview
- Table 272. Hikma Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)

- Table 273. Hikma Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 274. Hikma Recent Development
- Table 275. Pharmaniaga Berhad Company Information
- Table 276. Pharmaniaga Berhad Business Overview
- Table 277. Pharmaniaga Berhad Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)
- Table 278. Pharmaniaga Berhad Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 279. Pharmaniaga Berhad Recent Development
- Table 280. Hovid Berhad Company Information
- Table 281. Hovid Berhad Business Overview
- Table 282. Hovid Berhad Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)
- Table 283. Hovid Berhad Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 284. Hovid Berhad Recent Development
- Table 285. Duopharma Biotech Company Information
- Table 286. Duopharma Biotech Business Overview
- Table 287. Duopharma Biotech Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)
- Table 288. Duopharma Biotech Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 289. Duopharma Biotech Recent Development
- Table 290. Kotra Pharma Company Information
- Table 291. Kotra Pharma Business Overview
- Table 292. Kotra Pharma Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)
- Table 293. Kotra Pharma Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 294. Kotra Pharma Recent Development
- Table 295. HOE Pharmaceutical Company Information
- Table 296. HOE Pharmaceutical Business Overview
- Table 297. HOE Pharmaceutical Generic Drugs Revenue in Generic Drugs Business (2018-2023) & (US\$ Million)
- Table 298. HOE Pharmaceutical Revenue in Generic Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 299. HOE Pharmaceutical Recent Development
- Table 300. Y.S.P. Industries Company Information

Table 301. Y.S.P. Industries Business Overview

Table 302. Y.S.P. Industries Generic Drugs Revenue in Generic Drugs Business
(2018-2023) & (US\$ Million)

Table 303. Y.S.P. Industries Revenue in Generic Drugs Business (2018-2023) & (US\$
Million) Portfolio

Table 304. Y.S.P. Industries Recent Development

Table 305. Authors List of This Report

List Of Figures

LIST OF FIGURES

Figure 1. Research Methodology

Figure 2. Research Process

Figure 3. Key Executives Interviewed

Figure 4. Generic Drugs Product Picture

Figure 5. Global Generic Drugs Market Size Comparison by Type (2023-2029) & (US\$ Million)

Figure 6. Global Generic Drugs Market Share by Type: 2022 VS 2029

Figure 7. Prescription Product Picture

Figure 8. Non-Prescription Drugs Product Picture

Figure 9. Global Generic Drugs Market Size by Application (2023-2029) & (US\$ Million)

Figure 10. Global Generic Drugs Market Share by Application: 2022 VS 2029

Figure 11. Hospital Product Picture

Figure 12. Clinic Product Picture

Figure 13. Others Product Picture

Figure 14. Global Generic Drugs Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 15. Global Generic Drugs Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 16. Global Generic Drugs Market Share by Region: 2022 VS 2029

Figure 17. Global Generic Drugs Market Share by Players in 2022

Figure 18.

I would like to order

Product name: Generic Drugs Industry Research Report 2024

Product link: <https://marketpublishers.com/r/G2774009A9FAEN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G2774009A9FAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970